Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 20/20 | 0.99 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.91 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.90 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.90 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.90 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.90 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.90 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.90 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.90 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.90 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.90 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.90 |
| ▸ | ITK known ✓ | Q08881 | 1/20 | 0.90 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.90 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.90 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.90 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.90 |
| ▸ | MUSK | O15146 | 1/20 | 0.90 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.90 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL74122 | 1.00 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL72924 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29435035 | 0.95 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL74121 | 0.95 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL742377 | 0.95 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL72923 | 0.94 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29349937 | 0.94 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL1759300 | 0.93 | FLT3 (0.87) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL1759073 | 0.93 | FLT3 (0.87) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL75153 | 0.92 | FLT3 (0.84) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260119-B1 | COMBINATION METHOD FOR TREATING CANCER | DAIICHI SANKYO CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| US-10716790-B2 | Method for treating cancer by combined use | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-21 | — | — | US | claimed |
| EP-2521782-B1 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS | INST NAT SANTE RECH MED (FR) | 2019-04-10 | — | — | EP | claimed |
| EP-2903593-B1 | TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN | AMBIT BIOSCIENCES CORP (US) | 2018-03-21 | — | — | EP | claimed |
| EP-3260119-A1 | COMBINATION METHOD FOR TREATING CANCER | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-27 | — | — | EP | claimed |
| US-20170216302-A1 | METHOD FOR TREATING CANCER BY COMBINED USE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-03 | — | — | US | claimed |
| US-9675549-B2 | Tablet containing composite with cyclodextrin | AMBIT BIOSCIENCES CORPORATION (US) | 2017-06-13 | — | — | US | claimed |
| US-20150250720-A1 | TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-10 | — | — | US | claimed |
| US-9109227-B2 | FLT3 receptor antagonists for the treatment or the prevention of pain disorders | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-08-18 | — | — | US | claimed |
| US-20260048099-A1 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | THE US SECRETARY DEPARMENT OF HEALTH AND HUMAN SERVICE (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3260119-B1 | COMBINATION METHOD FOR TREATING CANCER | DAIICHI SANKYO CO LTD (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-3668867-B1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIV REGENSBURG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | UNIVERSITÄT REGENSBURG (DE) | 2022-07-12 | — | — | US | disclosed |
| EP-3898626-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20130005966-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP. (US) | 2013-01-03 | — | — | US | disclosed |
| EP-2521782-A1 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120258081-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2429524-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | Ambit Biosciences Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2011083124-A1 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010132787-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | FLT3, CSF3R, ABL1 | FLT3 1/4885KDR 48/4885ABL1 3/4885 |
| US-20150250720-A1 | TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN | HBZ, MCL1, HBB | FLT3 23/4885KDR 4043/4885ABL1 99/4885 |
| US-20260048099-A1 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | IL15RA, IL15, IL2RA | FLT3 4/4885KDR 310/4885ABL1 399/4885 |
| US-20120258081-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | FLT4, FLT1, CDK3 | FLT3 6/4885KDR 57/4885ABL1 44/4885 |
| US-20170216302-A1 | METHOD FOR TREATING CANCER BY COMBINED USE | FLT3, MDM2, TP53 | FLT3 1/4885KDR 281/4885ABL1 5/4885 |
| US-20130005966-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | FLT4, FLT1, FLT3 | FLT3 3/4885KDR 13/4885ABL1 132/4885 |
| US-10716790-B2 | Method for treating cancer by combined use | FLT3, MDM2, TP53 | FLT3 1/4885KDR 281/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.